WallStSmart
BHVN

Biohaven Ltd.

NYSE: BHVN · HEALTHCARE · BIOTECHNOLOGY

$9.08
-5.26% today

Updated 2026-06-05

Market cap
$1.72B
P/E ratio
P/S ratio
EPS (TTM)
$-5.57
Dividend yield
52W range
$7 – $19
Volume
2.2M

Biohaven Ltd. (BHVN) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item201720182019202020212022202320242025
Operating cash flow$-94.81M$-197.14M$-377.33M$-75.96M$-145.84M$-297.69M$-331.73M$-582.45M$-609.44M
Capital expenditures$541000.00$4.17M$2.53M$2.70M$938000.00$41.07M$3.05M$4.05M$715000.00
Depreciation
Stock-based comp$13.24M$16.93M$54.97M$29.50M$65.64M$193.56M$28.79M$71.96M$112.36M
Free cash flow$-95.36M$-201.31M$-379.87M$-78.65M$-146.78M$-338.76M$-334.77M$-586.50M$-610.15M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash$40.30M

Frequently asked questions

How much free cash flow does BHVN generate?

BHVN produced $-610.15M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is BHVN's balance sheet healthy?

BHVN holds $229.96M in cash and equivalents against $238.90M in long-term debt, on $52.07M of shareholder equity. That debt is best read against the cash flow the business throws off each year.